ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0257

Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia

Risa Wakiya1, Hiroki Ozaki2, Hiromi Shimada1, Shusaku Nakashima1, Taichi Miyagi3, Yusuke Ushio4, Koichi Sugihara5, Mao Mizusaki1, Rina Mino6, Kanako Chujo7, Ryoko Kagawa4, Hayamasa Yamaguchi4, Tomohiro Kameda1 and Hiroaki Dobashi1, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Department of Rheumatology, KKR Takamatsu Hospital, Kagawa, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 5Kagawa University, Miki-cho, Kita-gun, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan

Meeting: ACR Convergence 2023

Keywords: complement, IgG4 Related Disease, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hypocomplementemia (HC) is often observed in IgG4-related diseases (IgG4-RD), but there are also IgG4-RD without HC. This study aimed to clarify the difference of characteristics of IgG4-RD in the presence or absence of HC.

Methods: The data of patients diagnosed with IgG4-RD at our institution were retrospectively analyzed, and these patients were divided into two groups: the HC group, which comprised patients with decreased C3 or C4 level (hypocomplementemia), and nonHC group, which comprised patients with normal C3 and C4 levels. The characteristic, affected organs, blood and imaging findings, and treatment course of the patients in both groups were compared. As additional evaluation of IgG4RD feature using imaging modality, fluorodeoxyglucose (FDG)-PET/CT was conducted. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycation (TLG), which indicate the level of metabolic activity of the tumor, were measured to evaluate disease activity using FDG-PET/CT.

Results: The study enrolled 65 patients. Of these patients, 19 and 46 were included in the HC and nonHC groups, respectively. Table 1 shows the characteristics of patients with IgG4-RD in this study. The HC group had lower hemoglobin levels and platelet counts and higher serum IgG4, IgG, and sIL-2R levels compared than the nonHC group. Moreover, the number of patients requiring treatment was higher in the HC group (17 patients, 89%) than in the nonHC group (28 patients, 61%). Recurrence of IgG4-RD was observed in 3 of the 17 patients in the HC group and 11 of the 28 patients in the nonHC group. Two and three patients in the HC and nonHC groups, respectively, died during the course of this study.

Two of the three index that may reflect IgG4RD activity by analyzed by FDG-PET/CT were significantly higher in the HC group.

Although there was no significant difference in SUVmax between the two groups, the MTV and TLG were significantly higher in the HC group than those of nonHC group (Figure 1).

Conclusion: The HC group had peripheral blood cytopenia and higher IgG4 level than the nonHC group. Moreover, more patients in the HC group required therapeutic intervention and had a poor prognosis. In assessing the activity of patients with IgG4RD using FDG-PET/CT, HC group had higher disease activity compared with nonHC group.

Supporting image 1

Table 1. Characteristics of IgG4-RD patients in this study
P-values were determined using Mann-Whitney U test or Fisher’s exact test.

Supporting image 2

Differences in fluorodeoxyglucose-PET findings of the HC and nonHC groups
Maximum standardized uptake value was not significantly different between the groups; however, metabolic tumor volume and total lesion glycation were significantly higher in the HC group than in the nonHC groups.
The P-value was determined by performing the Mann–Whitney U test.


Disclosures: R. Wakiya: None; H. Ozaki: None; H. Shimada: None; S. Nakashima: None; T. Miyagi: None; Y. Ushio: None; K. Sugihara: None; M. Mizusaki: None; R. Mino: None; K. Chujo: None; R. Kagawa: None; H. Yamaguchi: None; T. Kameda: None; H. Dobashi: None.

To cite this abstract in AMA style:

Wakiya R, Ozaki H, Shimada H, Nakashima S, Miyagi T, Ushio Y, Sugihara K, Mizusaki M, Mino R, Chujo K, Kagawa R, Yamaguchi H, Kameda T, Dobashi H. Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/activity-of-igg4-related-disease-differs-depending-on-the-presence-or-absence-of-concomitant-hypocomplementemia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activity-of-igg4-related-disease-differs-depending-on-the-presence-or-absence-of-concomitant-hypocomplementemia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology